Vidipha Central Pharmaceutical JSC
Vidipha Central Pharmaceutical Joint Stock Company produces and sells pharmaceutical products under the Vidipha brand. It offers analgesics, antipyretics, gastrointestinal agents, antidiabetic agents, antibiotics, antivirals, antifungals, antihistamines, anti-allergic agents, respiratory agents, cardiovascular, neurological, antihypertensive agents, diuretics, vitamin, minerals, antiseptics, and … Read more
Market Cap & Net Worth: Vidipha Central Pharmaceutical JSC (VDP)
Vidipha Central Pharmaceutical JSC (VN:VDP) has a market capitalization of $22.16K (₫562.97 Million) as of March 19, 2026. Listed on the VN stock exchange, this Vietnam-based company holds position #25576 globally and #211 in its home market, demonstrating a 13.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vidipha Central Pharmaceutical JSC's stock price ₫56500.00 by its total outstanding shares 9964 (9.96K).
Vidipha Central Pharmaceutical JSC Market Cap History: 2017 to 2026
Vidipha Central Pharmaceutical JSC's market capitalization history from 2017 to 2026. Data shows change from $104.65K to $22.16K (-15.53% CAGR).
Vidipha Central Pharmaceutical JSC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vidipha Central Pharmaceutical JSC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VDP by Market Capitalization
Companies near Vidipha Central Pharmaceutical JSC in the global market cap rankings as of March 19, 2026.
Key companies related to Vidipha Central Pharmaceutical JSC by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Vidipha Central Pharmaceutical JSC Historical Marketcap From 2017 to 2026
Between 2017 and today, Vidipha Central Pharmaceutical JSC's market cap moved from $104.65K to $ 22.16K, with a yearly change of -15.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₫22.16K | -2.59% |
| 2025 | ₫22.75K | +56.76% |
| 2024 | ₫14.51K | -87.18% |
| 2023 | ₫113.17K | +4.75% |
| 2022 | ₫108.04K | -2.53% |
| 2021 | ₫110.84K | +24.37% |
| 2020 | ₫89.12K | -2.59% |
| 2019 | ₫91.50K | +1.12% |
| 2018 | ₫90.48K | -13.54% |
| 2017 | ₫104.65K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Vidipha Central Pharmaceutical JSC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.16K USD |
| MoneyControl | $22.16K USD |
| MarketWatch | $22.16K USD |
| marketcap.company | $22.16K USD |
| Reuters | $22.16K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.